UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington D.C. 20549
FORM SD
Specialized Disclosure Report
Mindray Medical International Limited
State or other jurisdiction of
incorporation
or organization:
Cayman Islands |
Commission File Number:
001-33036 |
IRS Employer Identification No. |
Mindray Building, Keji 12th Road South,
Hi-tech Industrial Park, Nanshan
Shenzhen 518057
People’s Republic of China
(Address
of principal executive offices)
Xiaobo Sun, telephone: +86 755 8188
8473
(Name and telephone number, including area code, of the person to contact in connection with this report.)
Check the appropriate box to indicate the rule pursuant to which
this form is being filed, and provide the period to which the information in this form applies:
x Rule 13p-1 under
the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2014.
Section 1 – Conflict Minerals Disclosure
This Form SD is filed by Mindray Medical International Limited
(“Mindray”) for the year ended December 31, 2014 (the “Reporting Period”) in accordance with Rule 13p-1
(“Rule 13p-1”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). Please refer to
Rule 13p-1, Form SD and the 1934 Act Release No. 34-67716 for definitions to the terms used in this Report, unless otherwise defined
herein.
A copy of Mindray’s Conflict Minerals Disclosure is provided
in this Item 1.01 and will be publicly available at www.mindray.com.
Item 1.01 Conflict Minerals Disclosure and Report, Exhibit
In accordance with Rule 13p-1, Mindray undertook a reasonable
country of origin inquiry (“RCOI”) to determine whether any of the conflict minerals necessary to the function or production
of the products that Mindray manufactured or contracted to manufacture during the Reporting Period originated in the Democratic
Republic of Congo or any of its adjoining countries (collectively, the “Covered Countries”), or were from recycled
or scrap sources. Rule 13p-1 defines conflict minerals as cassiterite, columbite-tantalite, gold, wolframite, and their derivatives
(limited to tantalum, tin and tungsten) (collectively, the “Conflict Minerals”).
Based on the RCOI, Mindray has determined in good faith that
for the Reporting Period, either the Conflict Minerals used in its products are “DRC conflict free,” it has “no
reason to believe that such Conflict Minerals originated in Covered Countries,” or it believes any Conflict Minerals incorporated
in their products are from “recycled or scrap sources” (terms as defined in the 1934 Act). As required by Form SD,
Mindray has indicated below such determination and described the related steps undertaken in connection with its RCOI.
Conflict Minerals Disclosure
Business/Product Overview
Mindray develops, manufactures, and markets medical devices.
Mindray has three primary product business segments—patient monitoring and life support products, in-vitro diagnostic products,
and medical imaging systems—and certain other products including orthopedic products, endoscope devices and healthcare IT
solutions products. Mindray’s products may be further categorized into medical equipment, accessories, and reagents. Mindray’s
reagents products and certain accessories do not contain any of the four Conflict Minerals. Mindray is several levels removed from
the actual mining of Conflict Minerals and does not make purchases of raw ore or unrefined Conflict Minerals and makes no purchases
in the Covered Countries.
Determination
Following a good faith RCOI, Mindray has determined for the
Reporting Period that its medical equipment and those accessories products which contain, or may contain, Conflict Minerals are
either DRC conflict free; the actual or potential Conflict Minerals are from recycled or scrap sources; or that Mindray has no
reason to believe that such actual or potential Conflict Minerals may have originated in a Covered Country.
Description and results of the RCOI
In undertaking the RCOI, Mindray first identified a list of
its suppliers of materials or parts contained in its products that either contained Conflict Minerals or where it was uncertain
whether Conflict Minerals were contained in those materials or parts. Mindray then distributed approximately 267 surveys to the
identified suppliers. The survey, among other things, requested the suppliers to identify the type(s), if any, of Conflict Minerals
included in the products/parts supplied to Mindray, and, if so, inquired whether such Conflict Mineral originated from a Covered
Country, whether such Conflict Mineral was from recycled or scrap sources, or whether such Conflict Mineral was from a conflicted
smelter. The survey was prepared based on the Electronic Industry Citizenship Coalition Global e-Sustainability Initiative (“EICC/GeSI”)
Conflict Minerals Reporting Template. Additionally, Mindray requested that the suppliers identify the smelters and refiners of
the Conflict Minerals contained in the relevant materials/parts and compared the identified smelters and refiners against the list
of smelter facilities which have been identified as “conflict free” by programs such as the EICC/GeSI Conflict Free
Smelter (CFS) program for tantalum, tin, tungsten and gold.
Mindray received an approximately 89% response rate in relation
to the distributed surveys, and reliable evidence and representations were provided by suppliers with respect to the provenance
of Conflict Minerals used in Mindray’s products. These survey responses and representations enabled Mindray to reach
the determination above, and in the process of obtaining such survey responses and representations, Mindray encountered no warning
signs or circumstances suggesting otherwise.
Mindray has adopted a Conflict Minerals Policy, a copy of which
is available at www.mindray.com. The content of Mindray’s website indicated
in this Form SD is for general information only and is not incorporated by reference herein.
Item 1.02 Exhibit
Not applicable.
Section 2 – Exhibits
Item 2.01 Exhibits
None.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Mindray Medical International Limited |
|
|
|
|
By: |
|
/s/ Alex Lung |
|
Name: |
|
Alex Lung |
|
Title: |
|
Chief Financial Officer |
|
Date: |
|
May 25, 2015 |
Montage Resources (NYSE:MR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Montage Resources (NYSE:MR)
Historical Stock Chart
From Apr 2023 to Apr 2024